Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
617 Views
They're Here: ESG Short Sellers
ESG short selling – i.e., shorting based on ESG metrics and catalysts – isn't new, but is undergoing a radical evolution. Short-term ESG trading...
549 Views
U. S. Equity Strategy: Small-Caps Closing the Gap
Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...
442 Views
Merries Baby Diaper Business: Struggles to Continue Despite Company Remarks a Quick Turnaround
Kao is a well-known Japanese conglomerate involved in various business activities ranging from FMCG products to chemicals. The company operates in...
562 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
592 Views